Molecular Diagnostics Market Size, Growth by Product & Service (Reagents, Kits, Instruments), Test Type (Lab, PoC), Technology (PCR, INAAT, NGS, ISH), Application (Infectious, Oncology, Genetic Testing), End User (Diagnostic Labs, Hospitals) & Region - Global Forecast to 2027
Instant Answers with GPT - Ask Now!
Ask real questions. Get complete answers !
Generating Response ...Updated on : March 27, 2023
The global molecular diagnostics market in terms of revenue was estimated to be worth $23.2 billion in 2022 and is poised to grow at a CAGR of 5.4% from 2022 to 2027.
In the past several years, the development and application of molecular diagnostic techniques have initiated a revolution in diagnosing and monitoring infectious diseases. Due to the high prevalence of infectious diseases, the demand for molecular diagnostic products and services is expected to increase in the coming years, which, in turn, will drive market growth.
To know about the assumptions considered for the study, Request for Free Sample Report
Molecular Diagnostics Market Dynamics
Drivers: Rising focus on R&D and growing funding in molecular diagnostics
Government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the molecular diagnostics market. For instance, NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, with a USD-200-million budget, was announced in August 2020. This initiative aimed to accelerate the development, commercialization, and implementation of technologies for COVID-19 testing. Additionally, in 2019, the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US NIH, initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program to support a broad portfolio of influenza research activities, including the development of vaccines, diagnostics, and therapeutics against seasonal and pandemic influenza. NIAID announced funds worth USD 51 million for CIVICs. Under the CIVICs program, investigators analyzed blood samples from people vaccinated against influenza and people diagnosed with the H1N1 influenza virus or H3N2 influenza viruses to check for vaccine effectiveness. As diagnostic testing is an integral part of infection control, the global market is expected to gain momentum in the near future. Such examples of funding and government initiatives are expected to support the growth of the market.
Opportunities: Growth opportunities in emerging countries
As markets in the US and Europe are maturing, most players are shifting their focus to emerging markets. The high investments in healthcare and life science research in emerging markets play an essential role in upgrading laboratory infrastructures in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growing adoption of molecular diagnostics.
Restraints: Unfavorable reimbursement scenario
According to MedPAC (Medicare Payment Advisory Commission), medical testing has seen a 40% decline in reimbursement over the last 40 years. This decline and additional budgetary concerns among healthcare systems will be a major obstacle to implementing novel diagnostic techniques in clinical laboratories.
The Centers for Medicare & Medicaid Services (CMS) reduced the Medicare reimbursement rate for COVID-19 tests based on high-throughput technology to USD 75 unless labs can process results in under two days. Medicare does not currently provide genetic testing coverage for individuals without a personal history of cancer (Source: American Society of Clinical Oncology). These factors are expected to affect the US molecular testing market adversely.
Challenges: Operational barriers
Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory spaces also need to be reconfigured to conduct specific molecular diagnostic tests used for pathogen detection to avoid cross-contamination and ensure efficient time management. This results in considerable cost escalations in maintaining and operating advanced molecular diagnostic instruments, particularly those capable of handling a single sample type.
Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the shortage of skilled and technically knowledgeable laboratory technicians to operate advanced molecular diagnostic products has hindered their overall adoption, particularly in emerging markets.
Molecular Diagnostics Market Ecosystem
To know about the assumptions considered for the study, download the pdf brochure
Reagents & kits segment to dominate the molecular diagnostics market
Reagents are essential components of all diagnostic analyses and generate accurate and precise test results. This is the largest and fastest-growing product segment in the global market. Molecular diagnostic reagents include disease-specific kits and general reagents used during infectious disease diagnosis and pathogen screening. Companies are now launching rapid kits and reagents to detect the novel coronavirus, which is further fueling the growth of this market segment. Regional authorities have also been actively engaged in providing emergency approvals for the use of these kits.
PoC tests segment of molecular diagnostics market is expected to have the highest CAGR during the forecast period
One of the main advantages of using PoC testing in hospitals or clinics over laboratory tests is that they have a faster turnaround time for testing than laboratory tests. Additionally, PoC testing requires lower sample volumes than traditional laboratory tests. Thus, the need to closely monitor patient conditions and advantages such as faster diagnosis are the major factors driving the demand for PoC tests.
Polymerase chain reaction segment to dominate the molecular diagnostics market
Polymerase chain reaction (PCR) is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours). The development of portable real-time PCR machines and assays for point-of-care (PoC) infectious disease diagnostics and cancer diagnostics is expected to propel the growth of the PCR market. However, amplification-based target enrichment, such as PCR, is susceptible to allele drop-out, resulting in false negatives. This is a drawback for PCR, resulting in the growth of other technologies such as probe-based enrichment methods.
Asia Pacific is expected to be the fastest growing region of molecular diagnostics market during the forecast period.
Low infrastructure & treatment costs and the availability of highly educated physicians have driven medical tourists to APAC countries. This is a major factor driving the growth of the molecular diagnostics market in this region. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.
However, factors such as the reluctance of healthcare professionals to adopt advanced diagnostic technologies due to budget constraints and pricing pressures faced by prominent product manufacturers are expected to restrain the market growth during the forecast period.
The key players in global market are F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), PerkinElmer, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Abbott Laboratories (US).
Molecular Diagnostics Market Report Scope:
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$ 23.2 billion |
|
Estimated Value by 2027 |
$ 30.2 billion |
|
Growth Rate |
Poised to grow at a CAGR of 5.4% |
|
Largest Share Segments |
|
|
Market Report Segmentation |
Product & Service, Test Type, Technology, Application, End User And Regional |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
This report categorizes the global molecular diagnostics market into the following segments and sub-segments:
By Product & Service
- Reagents & Kits
- Instruments
- Services & Software
By Test Type
- Lab Tests
- PoC Tests
By Technology
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- DNA Sequencing & Next- generation Sequencing (NGS)
- In Situ Hybridization (ISH)
- DNA Microarrays
- Other Technologies
By Application
-
Infectious Disease Diagnostics
- COVID-19
- Hepatitis
- HIV
- CT/NG
- HAI
- HPV
- Tuberculosis
- Influenza
- Other Infectious Diseases
-
Oncology Testing
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancers
- Genetic Testing
- Other Applications
By End User
- Diagnostic Laboratories
- Hospitals & Clinics
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Russia
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Recent Developments:
- In September 2021, F. Hoffmann-La Roche Ltd. (Switzerland) announced the acquisition of TIB Molbiol (Germany) to expand its PCR test portfolio with a wide range of assays for infectious diseases.
- In June 2021, QIAGEN N.V.(Netherlands) partnered with Verogen (US) to broaden its portfolio in NGS technologies.
- In June 2021, Hologic, Inc. (US) acquired Mobidiag Oy (Finland), an innovator in acute care molecular diagnostic testing. This acquisition will aid in expanding Hologic’s molecular diagnostics product portfolio.
- In November 2020, Hologic, Inc. (US) received additional FDA approval for the AptimaHIV-1 Quant Dx Assay for use as an aid in the diagnosis of HIV infection.
Frequently Asked Questions (FAQs):
What is the projected market value of the global molecular diagnostics market?
The global market of molecular diagnostics is projected to reach USD 30.2 billion.
What is the estimated growth rate (CAGR) of the global molecular diagnostics market for the next five years?
The global molecular diagnostics market is projected to grow at a Compound Annual Growth Rate (CAGR) of CAGR of 5.4% from 2022 to 2027.
What are the major revenue pockets in the molecular diagnostics market currently?
Low infrastructure & treatment costs and the availability of highly educated physicians have driven medical tourists to APAC countries. This is a major factor driving the growth of the molecular diagnostics market in this region. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 36)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.3 MARKETS COVERED
1.3.1 MOLECULAR DIAGNOSTICS : MARKET
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 42)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT: MOLECULAR DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY (Page No. - 55)
FIGURE 8 MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 60)
4.1 MARKET OVERVIEW
FIGURE 14 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
4.2 MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027
FIGURE 15 REAGENTS & KITS WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 MARKET, BY TEST TYPE, 2022 VS. 2027
FIGURE 16 THE LAB TESTS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.4 MARKET, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 17 THE PCR SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.5 MARKET, BY APPLICATION, 2022 VS. 2027
FIGURE 18 THE INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 MARKET, BY END USER, 2022 VS. 2027
FIGURE 19 THE DIAGNOSTIC LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.7 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 64)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics
5.2.1.3 Growing awareness of early disease diagnosis in developing countries
5.2.1.4 Rising technological advancements in molecular diagnostics
5.2.1.5 Increasing use of PoC diagnostic tests
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 High cost of instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers
5.2.4.3 Introduction of alternative technologies
5.2.5 IMPACT OF COVID-19 ON THE MOLECULAR DIAGNOSTICS MARKET
5.3 PRICING ANALYSIS
TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
5.4 PATENT ANALYSIS
FIGURE 22 LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 24 MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP
FIGURE 25 MARKET: ECOSYSTEM/MARKET MAP
5.7.1 MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REGULATORY LANDSCAPE
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2017–2021 (USD million)
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2017–2021 (USD million)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES & EVENTS IN 2022–2023
TABLE 10 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC
FIGURE 26 REVENUE SHIFT IN THE MOLECULAR DIAGNOSTICS MARKET
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS, BY END USER
FIGURE 27 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS, BY END USER
TABLE 11 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS, BY END USER (%)
5.14.2 BUYING CRITERIA
FIGURE 28 KEY BUYING CRITERIA, BY END USER
TABLE 12 KEY BUYING CRITERIA, BY END USER
5.15 CASE STUDIES
FIGURE 29 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 92)
6.1 INTRODUCTION
TABLE 13 MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 14 PRICES OF MOLECULAR DIAGNOSTIC PRODUCTS (2021)
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS—A KEY FACTOR PROPELLING MARKET GROWTH
TABLE 15 MOLECULAR DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST THE DEMAND FOR MOLECULAR DIAGNOSTIC INSTRUMENTS
TABLE 16 KEY INSTRUMENTS AVAILABLE IN THE MARKET
TABLE 17 MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 18 MOLECULAR DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION)
7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 98)
7.1 INTRODUCTION
TABLE 19 MARKET, BY TEST TYPE, 2020–2027 (USD MILLION)
7.2 LAB TESTS
7.2.1 HIGH BURDEN OF COVID-19 TO DRIVE MARKET GROWTH
TABLE 20 MARKET FOR LAB TESTS, BY REGION, 2020–2027 (USD MILLION)
7.3 POC TESTS
7.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENTAL GROWTH IN THE COMING YEARS
TABLE 21 MARKET FOR POC TESTS, BY REGION, 2020–2027 (USD MILLION)
8 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 102)
8.1 INTRODUCTION
8.1.1 PRIMARY NOTES
8.1.1.1 Key industry insights
TABLE 22 MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 POLYMERASE CHAIN REACTION (PCR)
8.2.1 GROWING USE OF PCR IN PROTEOMICS AND GENOMICS MAKES THIS THE LARGEST MARKET SEGMENT
TABLE 23 MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2027 (USD MILLION)
8.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
8.3.1 COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH
TABLE 24 MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
8.4.1 INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL GROWTH IN THIS MARKET SEGMENT
TABLE 25 MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION)
8.5 IN SITU HYBRIDIZATION (ISH)
8.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS— A KEY FACTOR DRIVING GROWTH
TABLE 26 MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2020–2027 (USD MILLION)
8.6 DNA MICROARRAYS
8.6.1 INTRODUCTION OF DNA MICROARRAYS HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 27 MARKET FOR DNA MICROARRAYS, BY REGION, 2020–2027 (USD MILLION)
8.7 OTHER TECHNOLOGIES
TABLE 28 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
9 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 111)
9.1 INTRODUCTION
TABLE 29 MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 30 MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
9.2.1 COVID-19
9.2.1.1 Growing burden of COVID-19 is a key factor driving market growth
TABLE 32 DISTRIBUTION OF TOTAL NUMBER OF CASES, BY COUNTRY
TABLE 33 MARKET FOR COVID-19 TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 MARKET FOR COVID-19 TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.2 HEPATITIS
9.2.2.1 Increasing adoption of advanced technologies for the diagnosis of hepatitis B to drive growth in this segment
TABLE 35 MARKET FOR HEPATITIS TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 36 MARKET FOR HEPATITIS TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.3 HIV
9.2.3.1 High global prevalence of HIV will drive the need for molecular diagnostic tests
TABLE 37 MARKET FOR HIV TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 MARKET FOR HIV TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.4 HAI
9.2.4.1 Rising burden of MRSA infections and the increasing adoption of technologically advanced HAI diagnostic tests will likely drive market growth
TABLE 39 MARKET FOR HAI TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 40 MARKET FOR HAI TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.5 CT/NG
9.2.5.1 CT/NG infections are the most common STDs worldwide—a key factor driving market growth
TABLE 41 MARKET FOR CT/NG TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 42 MARKET FOR CT/NG TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.6 HPV
9.2.6.1 Technological advancements such as rapid HPV diagnostics drive growth in this segment
TABLE 43 MARKET FOR HPV TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 44 MARKET FOR HPV TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.7 TUBERCULOSIS
9.2.7.1 Increasing burden of TB globally to propel the demand for MDx tests
TABLE 45 MARKET FOR TUBERCULOSIS TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 MARKET FOR TUBERCULOSIS TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.8 INFLUENZA
9.2.8.1 Rising focus on containing the spread of influenza to propel growth in this segment
TABLE 47 MARKET FOR INFLUENZA TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 48 MARKET FOR INFLUENZA TESTING, BY REGION, 2020–2027 (MILLION TESTS)
9.2.9 OTHER INFECTIOUS DISEASES
TABLE 49 MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
9.3 ONCOLOGY TESTING
TABLE 50 MARKET FOR ONCOLOGY TESTING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 MARKET FOR ONCOLOGY TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
9.3.1 BREAST CANCER
9.3.1.1 Increasing prevalence of breast cancer is a key driver for market growth
TABLE 52 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 53 MOLECULAR DIAGNOSTIC MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)
9.3.2 COLORECTAL CANCER
9.3.2.1 Rising focus on the development of companion diagnostic assays for colorectal cancer drives market growth
TABLE 54 MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION)
9.3.3 LUNG CANCER
9.3.3.1 Increasing research for lung cancer biomarkers to drive market growth
TABLE 55 MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION)
9.3.4 PROSTATE CANCER
9.3.4.1 Advancements in genomic technologies for the development of new biomarkers will drive the market growth
TABLE 56 MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION)
9.3.5 OTHER CANCERS
TABLE 57 GLOBAL CANCER INCIDENCE, 2020
TABLE 58 MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
9.4 GENETIC TESTING
9.4.1 GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 59 MARKET FOR GENETIC TESTING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.5 OTHER APPLICATIONS
TABLE 60 MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
10 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 133)
10.1 INTRODUCTION
TABLE 61 MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO DRIVE MARKET GROWTH
TABLE 62 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
10.3 HOSPITALS & CLINICS
10.3.1 INCREASING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 63 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
10.4 OTHER END USERS
TABLE 64 MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
11 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 138)
11.1 INTRODUCTION
TABLE 65 MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: MARKET SNAPSHOT
TABLE 66 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 Increasing prevalence of infectious diseases and cancer to drive market growth in the US
TABLE 73 US: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 74 US: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 75 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 76 US: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 77 US: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 78 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Availability of funding for genomics research makes Canada a sizeable market for molecular diagnostics
TABLE 79 CANADA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 80 CANADA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 81 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 82 CANADA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 83 CANADA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 85 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 87 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 88 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 89 EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 90 EUROPE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 91 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing healthcare expenditure to drive market growth in Germany
TABLE 92 GERMANY: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 93 GERMANY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 94 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 95 GERMANY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 GERMANY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Growing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK
TABLE 98 UK: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 99 UK: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 100 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 101 UK: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 UK: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising R&D expenditure in France to drive market growth
TABLE 104 FRANCE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 105 FRANCE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 106 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 107 FRANCE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 FRANCE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
TABLE 110 ITALY: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 111 ITALY: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 112 ITALY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 113 ITALY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 ITALY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5 RUSSIA
11.3.5.1 Increasing access to quality healthcare will support market growth in Russia
TABLE 116 RUSSIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 117 RUSSIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 118 RUSSIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 119 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 RUSSIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 RUSSIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Growing demand for genetic testing in Spain to create major growth opportunities for market players
TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 123 SPAIN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 124 SPAIN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 125 SPAIN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 126 SPAIN: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 128 ROE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 129 ROE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 ROE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 131 ROE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 ROE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 133 ROE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 31 APAC: MARKET SNAPSHOT
TABLE 134 APAC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 APAC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 136 APAC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 137 APAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 138 APAC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 APAC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 APAC: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
TABLE 141 CHINA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 142 CHINA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 143 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 144 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 145 CHINA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 147 JAPAN: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 148 JAPAN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 149 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 150 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 151 JAPAN: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
TABLE 153 INDIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 154 INDIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 155 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 156 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 INDIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 High prevalence of infectious diseases makes Australia a relatively large market in the APAC
TABLE 159 AUSTRALIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 160 AUSTRALIA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 161 AUSTRALIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 162 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 AUSTRALIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 165 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 166 ROAPAC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 167 ROAPAC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 168 ROAPAC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 ROAPAC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 170 ROAPAC: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
TABLE 171 LATIN AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 172 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 173 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 174 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 175 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 176 LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Improving healthcare infrastructure to drive the growth of the molecular diagnostics market in Brazil
TABLE 178 BRAZIL: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 179 BRAZIL: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 180 BRAZIL: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 181 BRAZIL: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 182 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183 BRAZIL: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Improving accessibility and affordability of healthcare services in Mexico makes it a favorable market for molecular diagnostics
TABLE 184 MEXICO: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 185 MEXICO: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 186 MEXICO: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 187 MEXICO: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 189 MEXICO: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 190 ROLATAM: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 191 ROLATAM: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 192 ROLATAM: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 193 ROLATAM: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 194 ROLATAM: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 ROLATAM: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
TABLE 196 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 197 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 199 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 200 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 201 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 215)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE GLOBAL MARKET
TABLE 202 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 32 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
12.4 MARKET SHARE ANALYSIS
12.4.1 MARKET
FIGURE 33 MARKET SHARE, BY KEY PLAYER (2021)
TABLE 203 MARKET: DEGREE OF COMPETITION
12.4.2 MARKET SHARE & RANKING ANALYSIS, BY TECHNOLOGY
12.4.2.1 Polymerase chain reaction (PCR)
FIGURE 34 GLOBAL MARKET SHARE FOR PCR, BY KEY PLAYER (2021)
12.4.2.2 DNA sequencing and NGS
FIGURE 35 GLOBAL MARKET SHARE FOR DNA SEQUENCING & NGS, BY KEY PLAYER (2021)
12.4.2.3 Isothermal nucleic acid amplification technology (INAAT)
TABLE 204 GLOBAL MARKET RANKING FOR INAAT, BY KEY PLAYER, 2021
12.4.2.4 In situ hybridization (ISH)
TABLE 205 GLOBAL MARKET RANKING FOR ISH, BY KEY PLAYER, 2021
12.4.3 MARKET RANKING ANALYSIS, BY APPLICATION
12.4.3.1 Infectious diseases
TABLE 206 GLOBAL MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2021
12.4.3.2 COVID-19
TABLE 207 GLOBAL MARKET RANKING FOR COVID-19, BY KEY PLAYER, 2021
12.5 COMPANY EVALUATION QUADRANT
12.5.1 LIST OF EVALUATED VENDORS
12.5.2 STARS
12.5.3 EMERGING LEADERS
12.5.4 PERVASIVE PLAYERS
12.5.5 PARTICIPANTS
FIGURE 36 MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 37 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
12.7 COMPETITIVE BENCHMARKING
12.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 38 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
TABLE 208 GLOBAL MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 209 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 210 COMPANY REGIONAL FOOTPRINT
TABLE 211 GLOBAL MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES
TABLE 212 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
12.8.2 DEALS
TABLE 213 KEY DEALS
13 COMPANY PROFILES (Page No. - 230)
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 F. HOFFMANN-LA ROCHE LTD
TABLE 214 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
13.1.2 HOLOGIC, INC.
TABLE 215 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 40 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
13.1.3 PERKINELMER, INC.
TABLE 216 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 41 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
13.1.4 ABBOTT LABORATORIES
TABLE 217 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.5 THERMO FISHER SCIENTIFIC, INC.
TABLE 218 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
13.1.6 QIAGEN N.V.
TABLE 219 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 44 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
13.1.7 SIEMENS HEALTHINEERS AG
TABLE 220 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
13.1.8 BIOMÉRIEUX SA
TABLE 221 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 46 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
13.1.9 MYRIAD GENETICS, INC.
TABLE 222 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2021)
13.1.10 DANAHER CORPORATION
TABLE 223 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 ILLUMINA, INC.
TABLE 224 ILLUMINA, INC.: COMPANY OVERVIEW
13.2.2 BECTON, DICKINSON AND COMPANY
TABLE 225 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
13.2.3 GRIFOLS, S.A.
TABLE 226 GRIFOLS, S.A.: COMPANY OVERVIEW
13.2.4 QUIDEL CORPORATION
TABLE 227 QUIDEL CORPORATION: COMPANY OVERVIEW
13.2.5 AGILENT TECHNOLOGIES, INC.
TABLE 228 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
13.2.6 DIASORIN S.P.A.
TABLE 229 DIASORIN S.P.A.: COMPANY OVERVIEW
13.2.7 EXACT SCIENCES CORPORATION
TABLE 230 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
13.2.8 GENETIC SIGNATURES
TABLE 231 GENETIC SIGNATURES: COMPANY OVERVIEW
13.2.9 MDXHEALTH
TABLE 232 MDXHEALTH: COMPANY OVERVIEW
13.2.10 HTG MOLECULAR DIAGNOSTICS, INC.
TABLE 233 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY OVERVIEW
13.2.11 BIOCARTIS NV
TABLE 234 BIOCARTIS NV: COMPANY OVERVIEW
13.2.12 TBG DIAGNOSTICS LIMITED
TABLE 235 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
13.2.13 VELA DIAGNOSTICS
TABLE 236 VELA DIAGNOSTICS: COMPANY OVERVIEW
13.2.14 AMOY DIAGNOSTICS CO., LTD.
TABLE 237 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
13.2.15 ELITECHGROUP
TABLE 238 ELITECHGROUP: COMPANY OVERVIEW
13.2.16 MOLBIO DIAGNOSTICS PVT. LTD.
TABLE 239 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
13.2.17 SAVYON DIAGNOSTICS
TABLE 240 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
13.2.18 ABACUS DIAGNOSTICA OY
TABLE 241 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
13.2.19 GENEOMBIO TECHNOLOGIES PVT. LTD.
TABLE 242 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
14 APPENDIX (Page No. - 294)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the molecular diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Molecular Diagnostics Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the molecular diagnostics market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Market Size: Top-Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the global molecular diagnostics market, by product & service, test type, technology, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall molecular diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Molecular diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa
Company profiles
- Additional five company profiles of players operating in the molecular diagnostics market.
Growth opportunities and latent adjacency in Molecular Diagnostics Market
• Due to covid, there was an increase in the demand for immunodiagnostics and molecular testing, which was regarded as the gold standard for diagnosing infectious diseases, leading to the increased sales of related consumables and kits. During the pandemic era, revenue growth for key players was majorly driven by the sales of COVID-19 diagnostic tests. The dominant model of laboratory testing throughout the world remains the centralized laboratory that uses automated analytical testing methods to detect target analytes. This trend is well established in clinical chemistry and haematology disciplines and is now extending to other areas, including immunoassays and molecular diagnostics. Reagents & kits segment accounted for the largest share in the IVD market and Oncology segment is expected to witness the fastest growth in the forecast period. With 30,000+ partners, technologies, and use-cases as the primary levers, we have deep understanding of IVD ecosystem. We offer more than 2X coverage throughout the IVD curve as compared to our competitors.
•The molecular diagnostics market is segmented into lab tests and PoC tests by test type. The lab tests segment accounted for the largest share of the molecular diagnostics market in 2021. Factors such as the increasing need for automation and the rising incidence of various infectious diseases are driving the growth of this segment. •Molecular diagnostic reagents include disease-specific kits and general reagents used during infectious disease diagnosis and pathogen screening. Laboratory technicians utilize specific disease diagnostic kits for earlier and more accurate identification of specific pathogen strains in a patient sample. General reagents are key components of a majority of conventional molecular diagnostic procedures. • Companies are now launching rapid kits and reagents to detect the novel coronavirus, which is further fueling the growth of this market segment. Regional authorities have also been actively engaged in providing emergency approvals for the use of these kits. In September 2020, Danaher Corporation (US) received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. In March 2020, QIAGEN N.V. (Netherlands) received FDA approval for its QIAstat-Dx test kit to detect coronavirus.